Home › IGA Glomerulonephritis › NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
RecruitingPhase 2
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Mean eGFR greater than or equal to 30 mL/min/1.73m2 * Clinical evidence of active kidney disease * Treated with supportive care including an ACE inhibitor or ARB if applicable * Willing to receive required vaccinations * Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy Exclusion Criteria: * Hereditary or acquired complement deficiency * Kidney transplant or renal replacement therapy * History of solid organ transplant * Other kidney disease * History of recurrent invasive infections * Received complement inhibitor treatments * Active systemic viral, bacterial, or fungal infection * Abnormal liver function
About the study
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
What is being tested
- ADX-038 Dose Level 2 (drug)
- ADX-038 Dose Level 1 (drug)
Sponsor: ADARx Pharmaceuticals, Inc. · Participants: 45 · Started: Aug 28, 2025
Contact the study team
- Tracy Nguyen · Phone: 877-232-7974
Official record on ClinicalTrials.gov — NCT06989359
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.